Dietary Iron & Exercise Performance (Non-Anaemic Iron Deficiency & Anaemia)
Dietary Iron & Exercise Performance (Non-Anaemic Iron Deficiency & Anaemia) is classified under Group A (Evidence-Supported Sports Nutrition & Ergogenic Aids). While specific physiological and performance benefits are supported in peer-reviewed sports nutrition literature, dietary supplements are not universally safe, cannot replace whole-food nutrition, and carry real risks of undeclared prohibited-substance contamination (10–25% of uncertified commercial supplements). Always consult a qualified physician, pharmacist, or accredited sports dietitian.
1. Generic or Accepted Substance Name & Classifications
Accepted Name: Dietary Iron & Exercise Performance (Non-Anaemic Iron Deficiency & Anaemia)
Common Names, Synonyms & Classifications: Ferrous Sulphate IP; Ferrous Ascorbate; Ferrous Fumarate IP; Ferrous Bisglycinate; Ferric Carboxymaltose (IV)
Section Classification: Group A — Evidence-Supported Sports Nutrition & Ergogenic Aids (PERF-A10)
2. Pharmacological Class
Essential Trace Element for Haemoglobin Oxygen Transport, Myoglobin Storage & Mitochondrial Cytochrome/Fe-S Enzymes
3. Mechanism of Action
Essential prosthetic component of erythrocytic haemoglobin (oxygen transport), muscular myoglobin (intramuscular oxygen diffusion), and mitochondrial oxidative phosphorylation enzymes (Complexes I–IV iron-sulfur clusters and cytochromes). Endurance athletes experience accelerated iron turnover due to repetitive foot-strike intravascular haemolysis, sweat/GI micro-bleeding, and post-exercise interleukin-6 (IL-6)-driven hepatic hepcidin surges (which degrade ferroportin and block duodenal iron absorption for 3–6 hours post-workout).
4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)
Pharmacological/Physiological Effect: Restores depleted serum ferritin, transferrin saturation, haemoglobin mass, and tissue oxidative enzyme activity in iron-deficient athletes. Proven Athletic Performance Benefit: Correcting documented Iron Deficiency Anaemia (IDA) or Stage 1/2 Non-Anaemic Iron Deficiency (IDNA, serum ferritin < 20–35 ng/mL) significantly restores impaired VO₂max, endurance time-trial performance, and energetics. CRITICAL SCIENTIFIC DISTINCTION: Iron supplementation in iron-replete athletes (normal ferritin and haemoglobin) provides ZERO performance enhancement and carries serious risks of oxidative organ damage and iron overload!
5. Quality of Scientific Evidence
Evidence Assessment: High / Level A Consensus for treating documented Iron Deficiency (IDA / IDNA); Zero Ergogenic Effect in Iron-Replete Athletes (IOC Consensus Statement & NLEM 2022)
6. Approved Medical Uses (Where Applicable)
Ferrous Sulphate IP, Ferrous Fumarate IP, and Folic Acid combinations are NLEM 2022 essential medicines for iron-deficiency anaemia and Anemia Mukt Bharat public health programmes.
7. Sports-Related Uses, Misuse Patterns & Contamination Risks
Medically supervised oral iron replacement (e.g., morning or alternate-day oral iron taken before exercise when hepcidin is lowest, co-administered with Vitamin C to reduce Fe³⁺ to Fe²⁺). DANGEROUS MISUSE: Unsupervised empirical self-medication with high-dose oral iron or illicit 'no-needle-policy violating' intravenous iron infusions in iron-replete athletes.
8. Adverse Effects & Serious Safety Risks
Oral: Epigastric pain, nausea, constipation or diarrhoea, and harmless black stools (iron sulphide). Chronic iron overload: Hepatic fibrosis/cirrhosis, cardiomyopathy, pancreatic beta-cell injury (bronze diabetes), and Arthropathy. Acute paediatric overdose (>20–60 mg/kg elemental iron) is a medical emergency requiring IV Deferoxamine.
9. Contraindications & Precautions
Hereditary haemochromatosis (HFE mutations), thalassaemia major/intermedia with transfusion haemosiderosis, haemolytic anaemias, and normal/elevated serum ferritin.
10. Drug Interactions
Forms insoluble chelates that markedly reduce absorption of Levothyroxine (space by >=4 h), Fluoroquinolones (Ciprofloxacin, Levofloxacin), Tetracyclines (Doxycycline), and Levodopa/Methyldopa. Calcium salts, phytates, polyphenols (tea/coffee), and PPIs/antacids reduce oral iron absorption.
11. Clinical & Laboratory Monitoring Considerations
Mandatory laboratory confirmation BEFORE starting iron: Complete Blood Count (Hb, MCV, MCH, RDW), Serum Ferritin (note: ferritin is an acute-phase reactant; test when CRP is normal and after a rest day), Serum Iron, and Transferrin Saturation (TSAT).
12. Dependence, Misuse or Withdrawal Concerns
No dependence.
13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)
Oral and parenteral therapeutic iron salts are official in IP 2022 and NLEM 2022 ([10.7], [10.15]); low-dose RDA nutritional iron supplements are regulated by FSSAI and ICMR-NIN.
14. Official WADA Prohibited-List Status
ORAL IRON IS NOT PROHIBITED. CRITICAL WADA M2.2 RULE: Intravenous (IV) iron infusions (e.g., Ferric Carboxymaltose, Iron Sucrose) exceeding 100 mL per 12-hour period (including the saline flush/diluent volume) are PROHIBITED AT ALL TIMES under WADA Method M2.2 unless administered during legitimate hospital admission or covered by an approved Therapeutic Use Exemption (TUE).
15. Authoritative Source References & Date of Last Verification
Date of Last Verification: 11 November 2026